Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14443433 | 0.85 | HDAC6 (0.38) | HDAC6HDAC1HDAC2HTR2CSLC6A4 | |
| SCHEMBL12665879 | 0.84 | HDAC6 (0.35) | HDAC6HDAC1HDAC2HTR2CSLC6A4 | |
| SCHEMBL16846576 | 0.82 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA14CACNA1G | |
| SCHEMBL14810373 | 0.81 | ACLY (0.35) | HDAC6HDAC1HDAC2HTR2CSLC6A4 | |
| SCHEMBL15511200 | 0.81 | DGAT1 (0.44) | HDAC6HDAC1HDAC2CA14CACNA1G | |
| SCHEMBL26272379 | 0.78 | ACLY (0.41) | HDAC6HDAC1HDAC2L3MBTL1CA14 | |
| SCHEMBL16825069 | 0.78 | CYP4F2 (0.41) | HDAC6HDAC1HDAC2 | |
| SCHEMBL24876166 | 0.78 | CA14 (0.39) | HDAC6HDAC1HDAC2HTR2CSLC6A4 | |
| SCHEMBL15584545 | 0.78 | HDAC6 (0.38) | HDAC6HDAC1HDAC2HTR2CSLC6A4 | |
| SCHEMBL15085762 | 0.76 | HDAC6 (0.40) | HDAC6HDAC1HDAC2HTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| CN-113105475-B | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| CN-113105475-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2021-07-13 | — | — | CN | disclosed |
| EP-3793551-A1 | OXADIAZOLE COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| EP-3083597-B1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | GRUENENTHAL GMBH (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-9562036-B2 | Fluoromethyl-substituted pyrrole carboxamides as CaV2.2 calcium channel blockers | Grünenthal GmbH (DE) | 2017-02-07 | — | — | US | disclosed |
| EP-3083612-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | Grünenthal GmbH (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-3083597-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | Grünenthal GmbH (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-20160289186-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | GRUENENTHAL GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160289214-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | Grünenthal GmbH (DE) | 2016-10-06 | — | — | US | disclosed |
| WO-2015090603-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015090600-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289186-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | TRPV1, CACNA1B, CACNA1I | HDAC6 331/4885HDAC1 618/4885HDAC2 664/4885 |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | HDAC6 294/4885HDAC1 203/4885HDAC2 620/4885 |
| US-20160289214-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNG2, CACNA1G | HDAC6 515/4885HDAC1 930/4885HDAC2 459/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | HDAC6 294/4885HDAC1 203/4885HDAC2 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.